AIATELLA

Big News! AIATELLA closes funding round to deliver breakthrough cardiovascular care technology While the capital will accelerate our progress significantly, what excites us most is having incredible partners who share our vision for transforming cardiovascular care. Led by existing investor Nordic Science Investments, along with Specialist VC, Harjavalta Ventures, Business Finland and an angel syndicate including those who have supported us from the early days. These investors aren't just providing funding, they're backing our commitment to transform how we approach cardiovascular health.   AIATELLA's technology addresses a critical challenge faced by radiologists worldwide in cardiovascular disease management. But we're not stopping there, we're enabling a fundamental shift toward preventative care. Our mission is both ambitious and essential: detecting cardiovascular issues before they escalate into life-threatening emergencies.   The cardiovascular disease landscape is ready for disruption. Too many people receive their first warning sign in an emergency room. Our technology can change that narrative, moving from reactive treatment to proactive prevention.   With this funding and the invaluable expertise and networks of our investors and advisors, we can now accelerate our mission at the pace it deserves. Together, we're building a future where cardiovascular health is monitored, predicted, and protected; not just treated after the fact.   The entire AIATELLA team is energised and ready to push the boundaries of what's possible in cardiovascular care. With the resources now in place, we're positioned to develop solutions that could transform millions of lives.

🏆 AIATELLA Wins Iceland Innovation Week 'Fermented Shark Tank' Competition! Iceland has produced some of the world's most groundbreaking cardiovascular research, with pioneering studies that have shaped our understanding of these diseases globally. We were thrilled to be in Iceland demonstrating our preventative cardiovascular screening technology to the country's leading researchers and the broader innovation community. Whilst there, Jack presented AIATELLA's vision in the pitching competition, with Jayesh explaining how our technology works under the hood. We were overwhelmed by the incredible response we received from Iceland's research and innovation community - and to win the competition! #CardiovascularResearch #Iceland #IcelandInnovationWeek #AIATELLA

Using AI to save lives. Transforming cardiovascular diagnostics & treatment worldwide.   Proud to partner with Microsoft at ChangeNOW 2025, showcasing AIATELLA's innovative solutions that enhance medical accuracy and accessibility.   Thank you Microsoft's Entrepreneurship for Positive Impact for amplifying technology that creates a healthier tomorrow for all. 🌍

At ChangeNOW 2025, we’re excited to showcase how AIATELLA is turning the prevention of cardiovascular disease from a distant policy goal into a real, actionable solution. Find Onni and Jack at the Microsoft's Entrepreneurship for Positive Impact booth, or on the Garden stage at 17:30 (CET) on Friday 25th where we'll discuss AIATELLA's mission to empower, not only healthcare systems worldwide, but we as individuals, to detect and intervene earlier than ever before.

Last week, we welcomed our pioneering #AcceleratingFemTech cohort to British Medical Association House for our second face-to-face event of the programme. Across the two days, we explored the FemTech landscape, including insightful talks on: 🖥️ Navigating digital censorship with CensHERship 💡 The importance of perfecting your pitch from Rebekah Lloyd 💰 Lavender Ventures on the FemTech investment landscape ✍ A masterclass from Alison Mlot on grant writing, ahead of the special closed call feasibility funding opportunity through Innovate UK Biomedical Catalyst We were also delighted to be joined by DigitalHealth.London alumni, including Smoke Free, TestCard.com and Isla Health | B Corp™, who shared their experiences of engaging with new markets. Our cohort also heard from #AcceleratingFemTech peers AIATELLA and Level Zero Health on their personal experiences of identifying and raising new funding. Thank you to all our speakers, partners, guests and innovators for making our second residential day so impactful, from creating new connections to sharing ideas and perspectives to shape the future of women's health. Learn more about #AcceleratingFemTech and the work our cohort are doing to push forward women's health: https://lnkd.in/eY9hN_um

We are delighted to announce that AIATELLA has been awarded a grant from the Instrumentariumin Tiedesäätiö sr. A private, non-profit organization that supports medical, technical, and scientific research. We would like to extend our gratitude to the grant award committee for recognising the importance of preventative approaches to cardiovascular disease, and supporting our work to make prevention accessible to all. This grant brings us closer to our goal of improving healthcare delivery in the community setting, and improving patient outcomes in Finland and beyond!

It was fantastic to celebrate the innovators recognised in the AI Visionaries 2025 list at the Responsible AI: Women and Healthcare Conference yesterday. Health Innovation Kent Surrey Sussex recently named the 2025 visionaries, highlighting leaders who are using AI to tackle sex bias in healthcare. HI NENC is proud to have supported Jack Parker, Founder of AIATELLA, whose groundbreaking work was recognised. Speakers such as Dame Lesley Regan and Kate Lancaster explored the urgent need to address women’s health inequalities and the potential role of AI in this. As Baroness Merron summed up: "We need to address the healthcare challenges of today using the technologies of the future."

Super proud of our CEO Jack being recognized as a visionary for the use of AI to close the gender health gap. At the forefront of AI in healthcare, AIATELLA has the opportunity (and therefore the obligation) to ensure representation in our AI and research. Cardiovascular diseases do not discriminate, so neither should AI! AIATELLA is committed to ensuring representation of women and minority populations in our research and product development, recognizing that clinical guidelines have typically been informed by studies on white, middle-aged men. We're running clinical studies focused on understanding barriers to care and investigating how diseases present and progress differently by sex and demographic. This commitment extends to our AI development, where we create inclusive algorithms that account for diverse populations. By collaborating with our clinical and academic partners, AIATELLA aims to make a significant contribution to changing the landscape of medical research and AI applications, ensuring that our innovations serve all segments of society equitably.

 Following our successful proof of concept at SLUSH last year, Onni and Jack had the opportunity to share our progress in making preventative CVD screening possible in the Finnish healthcare magazine Hoiva & Terveys   We're incredibly excited to enter the new year and pushing the quality of cardiovascular care and working towards making preventative CVD screening accessible to all!

Vision ➨ Reality in just 2 years This year at SLUSH, we experienced the profound impact our technology can have on real people, with real stories. This has always been our mission, and now we see it coming to fruition. SLUSH has always been a fantastic platform for connecting the ecosystem, sharing knowledge, and collaboration. However, this year meant so much more for us. Through a technical demonstration of carotid artery screening, we showed how our technology can detect cardiovascular issues that might otherwise go unnoticed, validating just how important this work is. The tangible impact of our work was highlighted during our CEO Jack's presentation on the Startup Stage. He emphasised our broader mission: to automate cardiovascular analysis and exponentiate productivity, ultimately expanding access to preventative screening. This approach enables us to identify diseases long before they become critical. On behalf of the whole team, we'd like to extend our deepest gratitude to: • Tiina Ketonen and Pihlajalinna for expert clinical oversight  • The whole team at Maria 01 for hosting us, and Sarita Runeberg for spreading the word! • The Nordic Science Investments team for their insights and support so far. We're already impacting lives! • Slush for providing an exceptional platform for innovation, special mention to Maryama Moalim • Every participant who took part in the demonstration - you have helped advance the future of AI-powered prevention If you're concerned about your cardiovascular risk or want to learn more about our technology, please reach out.